Who Paid My Doc
Ty Hargroder
Hospice and Palliative Medicine Eunice, LA Medical Doctor
NPI 1093761645 CMS profile 736341
3501 Highway 190 Ste X, Eunice, LA 70535
General payments
$4,388
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ty Hargroder of Eunice, LA is reported in the CMS Open Payments database as having received $4,388 across 86 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $310 | 11 | |
| 2024 | General | $2,492 | 24 | |
| 2023 | General | $737 | 14 | |
| 2022 | General | $118 | 5 | |
| 2021 | General | $361 | 11 | |
| 2020 | General | $322 | 16 | |
| 2019 | General | $48 | 5 |
Beside peers
- Ty Hargroder
- Hospice and Palliative Medicine median
- Middle half of Hospice and Palliative Medicine
- National median
In program year 2025, general payments to Ty Hargroder were reported at $310. Among 151 Hospice and Palliative Medicine profiles paid that year, the median was $79 and the middle half received between $28 and $179.
Show as a table
| Year | Ty Hargroder | Hospice and Palliative Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $48 | $70 | $20–$164 | $163 |
| 2020 | $322 | $67 | $19–$171 | $114 |
| 2021 | $361 | $81 | $22–$170 | $132 |
| 2022 | $118 | $92 | $29–$229 | $149 |
| 2023 | $737 | $98 | $33–$185 | $160 |
| 2024 | $2,492 | $68 | $24–$170 | $164 |
| 2025 | $310 | $79 | $28–$179 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 169 drugsPart D claims
9,564
Drug cost
$622,067
Branded share of claims
23.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 291 | $88,706 | |
| Humira(Cf) Pen Adalimumab | Brand | 12 | $85,375 | |
| Linzess Linaclotide | Brand | 68 | $38,548 | |
| Jardiance Empagliflozin | Brand | 109 | $33,892 | |
| Xarelto Rivaroxaban | Brand | 109 | $24,229 | |
| Rexulti Brexpiprazole | Brand | 29 | $24,128 | |
| Daptomycin | Generic | 12 | $19,772 | |
| Januvia Sitagliptin Phosphate | Brand | 67 | $19,489 | |
| Farxiga Dapagliflozin Propanediol | Brand | 68 | $19,433 | |
| Ertapenem Ertapenem Sodium | Brand | 22 | $18,782 |
The 10 drugs with the highest cost, of 169 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 53 billing codesPaid by Medicare
$349,557
Medicare patients
250
Services billed
2,724
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Depression | 65% | |
| Arthritis | 63% | |
| Diabetes | 54% | |
| Ischemic heart disease | 53% | |
| Heart failure | 44% | |
| Chronic kidney disease | 44% | |
| COPD | 43% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
86 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hospice and Palliative Medicine in Louisiana
Related records
Hospice and Palliative Medicine in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Hospice and Palliative Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.